These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 9498442)

  • 21. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.
    Brandler S; Ruffié C; Combredet C; Brault JB; Najburg V; Prevost MC; Habel A; Tauber E; Desprès P; Tangy F
    Vaccine; 2013 Aug; 31(36):3718-25. PubMed ID: 23742993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice.
    Samsa MM; Dupuy LC; Beard CW; Six CM; Schmaljohn CS; Mason PW; Geall AJ; Ulmer JB; Yu D
    Mol Ther; 2019 Apr; 27(4):850-865. PubMed ID: 30770173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine.
    Tretyakova I; Lukashevich IS; Glass P; Wang E; Weaver S; Pushko P
    Vaccine; 2013 Feb; 31(7):1019-25. PubMed ID: 23287629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenoviral-Vectored Mayaro and Chikungunya Virus Vaccine Candidates Afford Partial Cross-Protection From Lethal Challenge in A129 Mouse Model.
    Campos RK; Preciado-Llanes L; Azar SR; Kim YC; Brandon O; López-Camacho C; Reyes-Sandoval A; Rossi SL
    Front Immunol; 2020; 11():591885. PubMed ID: 33224148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine.
    Dupuy LC; Locher CP; Paidhungat M; Richards MJ; Lind CM; Bakken R; Parker MD; Whalen RG; Schmaljohn CS
    Vaccine; 2009 Jun; 27(31):4152-60. PubMed ID: 19406186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus.
    Reed DS; Lind CM; Lackemeyer MG; Sullivan LJ; Pratt WD; Parker MD
    Vaccine; 2005 May; 23(24):3139-47. PubMed ID: 15837213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric alphavirus vaccine candidates for chikungunya.
    Wang E; Volkova E; Adams AP; Forrester N; Xiao SY; Frolov I; Weaver SC
    Vaccine; 2008 Sep; 26(39):5030-9. PubMed ID: 18692107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.
    Metz SW; Martina BE; van den Doel P; Geertsema C; Osterhaus AD; Vlak JM; Pijlman GP
    Vaccine; 2013 Dec; 31(51):6092-6. PubMed ID: 24099875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An immunological profile of Balb/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan equine encephalitis virus vaccine.
    Bennett AM; Elvin SJ; Wright AJ; Jones SM; Phillpotts RJ
    Vaccine; 2000 Sep; 19(2-3):337-47. PubMed ID: 10930689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Robustness of Serologic Investigations for Chikungunya and Mayaro Viruses following Coemergence.
    Fischer C; Bozza F; Merino Merino XJ; Pedroso C; de Oliveira Filho EF; Moreira-Soto A; Schwalb A; de Lamballerie X; Netto EM; Bozza PT; Sarno M; Brites C; Gotuzzo E; Talledo M; Drexler JF
    mSphere; 2020 Feb; 5(1):. PubMed ID: 32024703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 1,5-Iodonaphthyl azide-inactivated V3526 protects against aerosol challenge with virulent venezuelan equine encephalitis virus.
    Gupta P; Sharma A; Spurgers KB; Bakken RR; Eccleston LT; Cohen JW; Honnold SP; Glass PJ; Maheshwari RK
    Vaccine; 2016 May; 34(25):2762-5. PubMed ID: 27129427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose.
    Roy CJ; Adams AP; Wang E; Plante K; Gorchakov R; Seymour RL; Vinet-Oliphant H; Weaver SC
    J Infect Dis; 2014 Jun; 209(12):1891-9. PubMed ID: 24403555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pseudotyped viruses permit rapid detection of neutralizing antibodies in human and equine serum against Venezuelan equine encephalitis virus.
    Kolokoltsov AA; Wang E; Colpitts TM; Weaver SC; Davey RA
    Am J Trop Med Hyg; 2006 Oct; 75(4):702-9. PubMed ID: 17038698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Boosting with an adenovirus-based vaccine improves protective efficacy against Venezuelan equine encephalitis virus following DNA vaccination.
    Perkins SD; O'Brien LM; Phillpotts RJ
    Vaccine; 2006 Apr; 24(17):3440-5. PubMed ID: 16527377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IRES-Containing VEEV Vaccine Protects Cynomolgus Macaques from IE Venezuelan Equine Encephalitis Virus Aerosol Challenge.
    Rossi SL; Russell-Lodrigue KE; Killeen SZ; Wang E; Leal G; Bergren NA; Vinet-Oliphant H; Weaver SC; Roy CJ
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003797. PubMed ID: 26020513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralizing antibody responses of humans and mice to vaccination with Venezuelan encephalitis (TC-83) virus.
    Fillis CA; Calisher CH
    J Clin Microbiol; 1979 Oct; 10(4):544-9. PubMed ID: 93607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate CHIKV Vaccine.
    Henss L; Yue C; Von Rhein C; Tschismarov R; Lewis-Ximenez LL; Dölle A; Baylis SA; Schnierle BS
    J Infect Dis; 2020 Apr; 221(10):1713-1723. PubMed ID: 31828322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.
    Goo L; Dowd KA; Lin TY; Mascola JR; Graham BS; Ledgerwood JE; Pierson TC
    J Infect Dis; 2016 Nov; 214(10):1487-1491. PubMed ID: 27655868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidemiology of Emergent Madariaga Encephalitis in a Region with Endemic Venezuelan Equine Encephalitis: Initial Host Studies and Human Cross-Sectional Study in Darien, Panama.
    Vittor AY; Armien B; Gonzalez P; Carrera JP; Dominguez C; Valderrama A; Glass GE; Beltran D; Cisneros J; Wang E; Castillo A; Moreno B; Weaver SC
    PLoS Negl Trop Dis; 2016 Apr; 10(4):e0004554. PubMed ID: 27101567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.
    Chen GL; Coates EE; Plummer SH; Carter CA; Berkowitz N; Conan-Cibotti M; Cox JH; Beck A; O'Callahan M; Andrews C; Gordon IJ; Larkin B; Lampley R; Kaltovich F; Gall J; Carlton K; Mendy J; Haney D; May J; Bray A; Bailer RT; Dowd KA; Brockett B; Gordon D; Koup RA; Schwartz R; Mascola JR; Graham BS; Pierson TC; Donastorg Y; Rosario N; Pape JW; Hoen B; Cabié A; Diaz C; Ledgerwood JE;
    JAMA; 2020 Apr; 323(14):1369-1377. PubMed ID: 32286643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.